siRNA Peptide Docking Vehicle for AGT Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertension often require multiple antihypertensive drugs and face complications due to upregulation of counterbalancing mechanisms, with the upstream component of the renin-angiotensin-aldosterone system (RAAS) pathway, angiotensinogen (AGT), being difficult to modulate using existing pharmacological interventions.
Innovation Solution
Development of a conjugate containing a peptide covalently coupled to both an siRNA duplex and an N-acetyl-galactosamine (GalNAc) moiety, specifically targeting AGT mRNA for reduction of AGT production, using a peptide docking vehicle (PDoV) for targeted delivery to hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological interventions are used to target downstream RAAS components, then blood pressure reduction is achieved, but counterbalancing mechanisms are upregulated and treatment complexity increases
Solution Approach 1:
The invention segments the RAAS pathway targeting by focusing exclusively on the upstream AGT component rather than treating multiple downstream components separately. This single-point upstream intervention simplifies the overall treatment approach while maintaining effective blood pressure control, avoiding the need for multiple antihypertensive drugs that currently trigger counterbalancing mechanisms.
Solution Approach 2:
The siRNA-based approach performs preliminary action by silencing AGT expression before the RAAS pathway is activated. By preventing AGT production at the transcriptional level, the pathway cannot be fully activated, thereby avoiding the need for downstream interventions and preventing the upregulation of counterbalancing mechanisms that occur with conventional downstream-targeting therapies.
2Reliability
If AGT is targeted using conventional pharmacological approaches, then upstream modulation is achieved, but delivery difficulty and pharmacological complexity increase
Solution Approach 1:
The invention replaces conventional pharmacological mechanisms with RNA interference technology. Instead of using small-molecule drugs that struggle to penetrate cell membranes and achieve sustained AGT suppression, the patent employs siRNA molecules that directly target AGT mRNA for degradation. This substitution enables more effective and sustained upstream modulation with simpler formulation requirements.
Solution Approach 2:
The invention changes the fundamental parameter of gene modulation from protein-level inhibition (pharmacological) to mRNA-level silencing (RNAi). This parameter change enables direct and permanent suppression of AGT expression without the need for continuous pharmacological intervention, thereby simplifying the overall therapeutic approach while maintaining reliable AGT modulation.
3Reliability
If multiple antihypertensive drugs are administered, then comprehensive blood pressure control is achieved, but treatment complexity and side effects increase
Solution Approach 1:
The invention extracts and isolates the single most effective target (AGT) from the complex RAAS pathway, rather than attempting to control multiple downstream components simultaneously. By focusing exclusively on upstream AGT silencing, the therapy achieves comprehensive blood pressure control through a single mechanism, eliminating the need for multiple drugs and their associated interactions and side effects.
Solution Approach 2:
The invention converts the potential harm of pathway activation into a benefit by preventing it at the source. Instead of allowing RAAS activation and then counteracting downstream effects with multiple drugs, the siRNA approach prevents AGT production beforehand, turning what would be a complex multi-drug treatment scenario into a single-agent therapy that inherently avoids the harmful interactions and side effects of combination pharmacotherapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA conjugate effectively reduces AGT production, providing a potentially superior treatment for hypertension that is free from the complications of current pharmaceutical approaches, with demonstrated efficacy in reducing blood pressure.
Implementation Method 1
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism that uses small double-stranded RNA molecules to direct gene silencing in a homology-based manner. Small interfering RNAs (siRNAs) recruit an RNA-induced silencing complex to the target mRNA, which then undergoes site-specific cleavage and degradation
Implementation Method 2
tri-antennary N-acetylgalactosamine (GalNAc) could mediate highly efficient targeted delivery of siRNAs to hepatocytes via binding to the asialoglycoprotein receptor
Data Source
AI summary
siRNA molecules targeting AGT mRNA that reduce or inhibit AGT production are provided. Pharmaceutical compositions containing such siRNA molecules also are provided, together with methods of their use for treating hypertension. Pharmaceutical compositions containing at least one oligonucleotide covalently linked to, and delivered to a target cell by, a peptide docking vehicle (PDoV) are capable of reducing or inhibiting the production of AGT and treating hypertension. The PDoV may contain a targeting ligand such as a GalNAc moiety conjugated to the PDoV which targets the complex to hepatocytes.